Literature DB >> 8843807

Speaking about pharmacovigilance.

D McNamee.   

Abstract

Mesh：

Year:  1996        PMID： 8843807     DOI： 10.1016/S0140-6736(05)65336-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

Review 1.  Pharmacovigilance in perspective.

Authors:  R H Meyboom; A C Egberts; F W Gribnau; Y A Hekster
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.606

2.  The role of the WHO programme on International Drug Monitoring in coordinating worldwide drug safety efforts.

Authors:  S Olsson
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

Review 3.  The challenge of effectively communicating risk-benefit information.

Authors:  I R Edwards; B Hugman
Journal:  Drug Saf       Date:  1997-10       Impact factor: 5.606

Review 4.  Good practice in the postmarketing surveillance of medicines.

Authors:  R H Meyboom
Journal:  Pharm World Sci       Date:  1997-08

5.  A pharmacovigilance study in medicine department of tertiary care hospital in chhattisgarh (jagdalpur), India.

Authors:  H Singh; N Dulhani; Bn Kumar; P Singh; P Tewari; K Nayak
Journal:  J Young Pharm       Date:  2010-01

6.  Adverse Drug Reactions (ADR) in the inPatients of Medicine Department of a Rural Tertiary Care Teaching Hospital and Influence of Pharmacovigilance in Reporting ADR.

Authors:  A P Gor; S V Desai
Journal:  Indian J Pharmacol       Date:  2008-01       Impact factor: 1.200
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.